|
As a supervisory board member of governmental foundations (such as the Netherlands Genomics Initiative), of the Dutch BioGeneration Ventures Fund, and by having worked together with UK and USA based venture capital firms, Koen Wiedhaup is actively involved in the creation of new life sciences companies. He serves or served on the supervisory and advisory boards of various biotech companies in the USA and Europe, several of which have meanwhile successfully completed an IPO. Wiedhaup is member of advisory councils of several Dutch universities, member of the supervisory board of the CWZ-hospital in Nijmegen and was vice-chairman of the supervisory board of the Academic Medical Centre Maastricht until 2007.
Prior to his current activities Dr. Wiedhaup was Group Director of the Pharma group of Akzo-Nobel from 1994 to early 2000. His responsibilities included R&D, Technology and Strategic Planning. From 1977 till 1994 he was, as a member of the board of management of Organon, responsible for Organon's Global R&D organization. He joined Organon in 1969 after having obtained his Ph.D. at the University of Amsterdam, and having held positions at the San Francisco Medical Center of the University of California, at Stanford University, California, and with Unilever in Rotterdam and London. | 